Herbert Tendayi Mapira, Joseph Musangwa, Anselme Mugenga, Jessca Umurerwa, Dominique Ufitikirezi, Cuthbert Musarurwa
{"title":"卢旺达胡耶市Kabutare地区医院2型糖尿病患者血脂异常和心血管疾病危险因素的评估","authors":"Herbert Tendayi Mapira, Joseph Musangwa, Anselme Mugenga, Jessca Umurerwa, Dominique Ufitikirezi, Cuthbert Musarurwa","doi":"10.4314/rjmhs.v7i3.8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dyslipidaemia is a major contributing factor to the development of cardiovascular disease (CVD) in type 2 diabetic mellitus (T2DM) patients. People with T2DM are at a significantly high risk of developing dyslipidaemia which in turn is a risk factor for CVD. The objective of this study was to assess the risk factors for CVD in T2DM patients.</p><p><strong>Methodology: </strong>A descriptive cross-sectional study was conducted on 100 T2DM patients consecutively presenting at Kabutare District Hospital, Huye District southern Rwanda. Excluded were patients on lipid lowering drugs and those with chronic renal and liver diseases.</p><p><strong>Results: </strong>The overall prevalence of dyslipidaemia was 79% with hypoalphalipoproteinaemia (47%) being the most common and hypercholesterolaemia (29%) the least frequent. When stratified according to glycaemic control, median diastolic blood pressure was significantly higher (p=0.045) in participants whose median fasting plasma glucose (FPG) was ≥5.6 mmol/L. Median fasting triglycerides (p=0.006) and non-HDL-C (p=0.019) concentrations were significantly lower in euglycaemic participants compared to participants with median FPG ≥5.6 mmol/L. Dysglycaemia was significantly associated with dyslipidaemia status (p=0.001).</p><p><strong>Conclusion: </strong>Effective management and monitoring of dyslipidaemia, particularly among those with poor glycaemic control, is crucial in mitigating CVD risks in this population.</p>","PeriodicalId":520910,"journal":{"name":"Rwanda journal of medicine and health sciences","volume":"7 3","pages":"471-484"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12110474/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessment of Dyslipidaemia and Cardiovascular Disease Risk Factors among Type 2 Diabetes Mellitus Patients Attending Kabutare District Hospital, Huye, Rwanda.\",\"authors\":\"Herbert Tendayi Mapira, Joseph Musangwa, Anselme Mugenga, Jessca Umurerwa, Dominique Ufitikirezi, Cuthbert Musarurwa\",\"doi\":\"10.4314/rjmhs.v7i3.8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Dyslipidaemia is a major contributing factor to the development of cardiovascular disease (CVD) in type 2 diabetic mellitus (T2DM) patients. People with T2DM are at a significantly high risk of developing dyslipidaemia which in turn is a risk factor for CVD. The objective of this study was to assess the risk factors for CVD in T2DM patients.</p><p><strong>Methodology: </strong>A descriptive cross-sectional study was conducted on 100 T2DM patients consecutively presenting at Kabutare District Hospital, Huye District southern Rwanda. Excluded were patients on lipid lowering drugs and those with chronic renal and liver diseases.</p><p><strong>Results: </strong>The overall prevalence of dyslipidaemia was 79% with hypoalphalipoproteinaemia (47%) being the most common and hypercholesterolaemia (29%) the least frequent. When stratified according to glycaemic control, median diastolic blood pressure was significantly higher (p=0.045) in participants whose median fasting plasma glucose (FPG) was ≥5.6 mmol/L. Median fasting triglycerides (p=0.006) and non-HDL-C (p=0.019) concentrations were significantly lower in euglycaemic participants compared to participants with median FPG ≥5.6 mmol/L. Dysglycaemia was significantly associated with dyslipidaemia status (p=0.001).</p><p><strong>Conclusion: </strong>Effective management and monitoring of dyslipidaemia, particularly among those with poor glycaemic control, is crucial in mitigating CVD risks in this population.</p>\",\"PeriodicalId\":520910,\"journal\":{\"name\":\"Rwanda journal of medicine and health sciences\",\"volume\":\"7 3\",\"pages\":\"471-484\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12110474/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rwanda journal of medicine and health sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4314/rjmhs.v7i3.8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rwanda journal of medicine and health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/rjmhs.v7i3.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:血脂异常是2型糖尿病(T2DM)患者发生心血管疾病(CVD)的主要因素。2型糖尿病患者发生血脂异常的风险非常高,而血脂异常又是心血管疾病的危险因素。本研究的目的是评估2型糖尿病患者心血管疾病的危险因素。方法:对卢旺达南部胡耶区Kabutare地区医院连续就诊的100例2型糖尿病患者进行了描述性横断面研究。排除了服用降脂药物的患者和患有慢性肾脏和肝脏疾病的患者。结果:血脂异常的总体患病率为79%,其中低脂蛋白血症(47%)最常见,高胆固醇血症(29%)最不常见。当根据血糖控制分层时,中位空腹血糖(FPG)≥5.6 mmol/L的参与者中位舒张压显著升高(p=0.045)。与中位FPG≥5.6 mmol/L的受试者相比,空腹甘油三酯(p=0.006)和非hdl - c (p=0.019)浓度中位数在血糖升高的受试者中显著降低。血糖异常与血脂异常状态显著相关(p=0.001)。结论:有效的管理和监测血脂异常,特别是那些血糖控制不良的人群,对于降低这一人群的心血管疾病风险至关重要。
Assessment of Dyslipidaemia and Cardiovascular Disease Risk Factors among Type 2 Diabetes Mellitus Patients Attending Kabutare District Hospital, Huye, Rwanda.
Background: Dyslipidaemia is a major contributing factor to the development of cardiovascular disease (CVD) in type 2 diabetic mellitus (T2DM) patients. People with T2DM are at a significantly high risk of developing dyslipidaemia which in turn is a risk factor for CVD. The objective of this study was to assess the risk factors for CVD in T2DM patients.
Methodology: A descriptive cross-sectional study was conducted on 100 T2DM patients consecutively presenting at Kabutare District Hospital, Huye District southern Rwanda. Excluded were patients on lipid lowering drugs and those with chronic renal and liver diseases.
Results: The overall prevalence of dyslipidaemia was 79% with hypoalphalipoproteinaemia (47%) being the most common and hypercholesterolaemia (29%) the least frequent. When stratified according to glycaemic control, median diastolic blood pressure was significantly higher (p=0.045) in participants whose median fasting plasma glucose (FPG) was ≥5.6 mmol/L. Median fasting triglycerides (p=0.006) and non-HDL-C (p=0.019) concentrations were significantly lower in euglycaemic participants compared to participants with median FPG ≥5.6 mmol/L. Dysglycaemia was significantly associated with dyslipidaemia status (p=0.001).
Conclusion: Effective management and monitoring of dyslipidaemia, particularly among those with poor glycaemic control, is crucial in mitigating CVD risks in this population.